Five Star Equities Issues New Research Reports on CCXI, NSTG, TTM and XNPT


Follow this company

Companies Mentioned

NASDAQ:CCXI / NASDAQ:NSTG / NYSE:TTM / NASDAQ:XNPT
09/11/2013 [ACCESSWIRE]

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.

ChemoCentryx Inc. (NASDAQ: CCXI) shares dropped 24.33 percent to close at $6.25 a share Tuesday. The stock traded between $6.06 and $6.78 on volume of 1.51 million shares traded. The company reported Phase II trial results for CCX140 that fell short of expectations. Shares of ChemoCentryx have fallen approximately 43.0 percent year-to-date.

Get more information on ChemoCentryx and free access to the in-depth equity report at:  
www.FiveStarEquities.com/CCXI

NanoString Technologies Inc. (NASDAQ: NSTG) shares soared 66.40 percent to close at $12.68 a share Tuesday. The stock traded between $8.29 and $14.10 on volume of 936,581 shares traded. The company announced that it has received 510(k) clearance from the FDA for its Prosigna Breast Cancer Prognostic Gene Signature Assay.

Get more information on NanoString Technologies and free access to the in-depth equity report at:  
www.FiveStarEquities.com/NSTG

Tata Motors Limited (NYSE: TTM) shares spiked 5.93 percent to close at $26.63 a share Tuesday. The stock traded between $26.45 and $26.83 on volume of 2.58 million shares traded. The company announced that it has launched in the Indonesian automotive industry with three new exciting Tata passenger vehicles -- the Tata Aria, the Tata Vista and the Tata Safari Storme. Shares of Tata Motors have fallen approximately 7.0 percent year-to-date.

Get more information on Tata Motors and free access to the in-depth equity report at:  
www.FiveStarEquities.com/TTM

XenoPort, Inc. (NASDAQ: XNPT) shares surged 17.10 percent to close at $5.89 a share Tuesday. The stock traded between $5.10 and $6.08 on volume of 1.64 million shares traded. The company released positive preliminary results of a Phase 1 study of its multiple sclerosis treatment, XP23829. Shares of XenoPort have fallen approximately 24.0 percent year-to-date.

Get more information on XenoPort and free access to the in-depth equity report at:  
www.FiveStarEquities.com/XNPT

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:             
Five Star Equities
info@fivestarequities.com

COMMENTS

Leave a comment...
 * 

Your Name
 *